03:43 PM EDT, 06/14/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Friday it won permanent injunctions from a district court against the US launch of Yesafili, which is a biosimilar ophthalmic drug to the company's Eylea product.

The US District Court for the Northern District of West Virginia also granted Regeneron's petition for a preliminary injunction against Samsung Bioepis' eye disease drug Opuviz, another biosimilar to Eylea, Regeneron said.

The court granted Regeneron's petition for permanent injunction in a sealed decision Tuesday against Biocon Biologics and Mylan Pharmaceuticals, which have filed a biologics license application with the US Food and Drug Administration to market Yesafili.

In a patent infringement case filed by Regeneron against Biocon and Mylan, the court ruled last year that certain claims of the formulation patent were held valid and infringed.

"We are pleased with the decision from the court regarding injunctions. Regeneron has invested many years of effort into its design and development of Eylea" with "numerous patents recognize that our important research and innovations," the company in a statement to MT Newswires.

Samsung Bioepis, Biocon and Mylan didn't immediately reply to requests for comment by MT Newswires.

Regeneron shares rose 1% in recent trading Friday.

Price: 1036.55, Change: +10.00, Percent Change: +0.97